Therefore, we estimated AFP-L3 levels using a newly developed method involving glycan microarray technology, and then we evaluated associations between the resultant assay values and clinical features such as HCC development to determine the usefulness of this measure for HCC detection. This evidence concerns the gene AFP and hepatocellular carcinoma.